Long‐term outcomes of autologous stem cell transplantation for peripheral T‐cell lymphomas across the Thames Valley (1997–2012)

@article{Sims2015LongtermOO,
  title={Long‐term outcomes of autologous stem cell transplantation for peripheral T‐cell lymphomas across the Thames Valley (1997–2012)},
  author={Matthew Sims and Kathryn Newell and Toby Andrew Eyre and Chris S. R. Hatton and Graham P Collins},
  journal={British Journal of Haematology},
  year={2015},
  volume={169}
}
Adrian Bloor Erwin De Cock Anthony J Hatswell Radek Wasiak Jamie Elvidge Ceilidh Stapelkamp Tsveta Hadjivassileva Amin Haiderali Julio Delgado Department of Haematology, The Christie NHS Foundation Trust, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, UK, United BioSource Corporation, Barcelona, Spain, BresMed Health Solutions, Sheffield, Evidera, Oncology, GlaxoSmithKline, London, UK, Oncology, GlaxoSmithKline, Collegeville, PA, USA and Department of… 

Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas

Subgroup analysis revealed that HDT/ASCT could improve the survival of patients with angioimmunoblastic T-cell lymphoma (AITL) and NKTCL, especially in patients with chemosensitivity.

[Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS)].

  • T. Kinoshita
  • Biology, Medicine
    Nihon rinsho. Japanese journal of clinical medicine
  • 2014
Current standard chemotherapies for aggressive B-cell lymphoma, such as CHOP, are the commonly used regimens for PTCL-NOS, but their efficacies were insufficient and no standard treatment has been established.

Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T-Cell Lymphomas As Front-Line Consolidation or in the Relapsed/Refractory Setting: A Meta-Analysis

A systematic review/meta-analysis of the published literature using PUBMED/MEDLINE evaluated the efficacy of HDT/auto-HCT in various histologic subtypes both as front-line consolidation and in R/R disease.

Autologous stem cell transplantation in first complete remission may not extend progression‐free survival in patients with peripheral T cell lymphomas

For PTCL patients achieving CR1 following CHOP‐like induction chemotherapy, ASCT does not appear to improve progression‐free survival compared to active observation, and this finding should be confirmed in a larger, prospective study.

Enteropathy-associated T-cell lymphoma (EATL)の病理

People with coeliac disease should follow a gluten-free diet to avoid damage to the small bowel.

References

SHOWING 1-10 OF 10 REFERENCES

The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study

It is demonstrated that high-dose chemotherapy with autologous stem cell rescue has a substantial role in the management of T-cell lymphoma, and exploration of reduced intensity regimens is warranted.

Autologous stem cell transplant for relapsed and refractory peripheral T‐cell lymphoma: variable outcome according to pathological subtype

While ASCT in patients with relapsed or primary refractory PTL results in long‐term remission rates comparable to DLBL patients, those with PTL‐NOS do significantly worse.

Guidelines for the management of mature T‐cell and NK‐cell neoplasms (excluding cutaneous T‐cell lymphoma)

There is no consensus about optimal therapy for T‐ and NK‐cell neoplasms and recommendations in this guideline are therefore based on small case series, phase II trials and expert opinion.

High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience.

Salvage treatment results with HDC/ASCT in PTCL are similar to those found in corresponding aggressive B-cell lymphomas and the utility of the pre-transplant IPI system in predicting outcome is confirmed.

Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation

It is indicated that up-front high-dose therapy and ASCT are feasible, but could induce a high rate of long-term CR only in patients with ALK-positive ALCL and the achievement of CR before autografting is a strong predictor of better survival.

Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.

Early-stage disease and initial treatment response as dominant prognostic factors in PTCL are identified and no clear benefit was observed for patients undergoing consolidative SCT.

High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma

In the experience, high-dose therapy and ASCT does not produce long-term DFS in patients with recurrent chemotherapy-sensitive ALK-negative ALCL, and primary systemic anaplastic lymphoma kinase (ALK)-negative anaPLastic large-cell lymphoma (ALCL) has a poor prognosis.

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.

The use of an anthracycline-containing regimen was not associated with an improved outcome in PTCL-NOS or angioimmunoblastic type, but was associated with a better outcome in anaplastic large-cell lymphoma, ALK positive.

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.

Patients with ALK-negative ALCL, PTCLU, or AITL presenting with IPI > 1 have a poor prognosis and should be considered candidates for novel treatment strategies.

Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.

Dose-dense induction followed by HDT/ASCT was well tolerated and led to long-term PFS in 44% of treatment-naive patients with PTCL, which represents an encouraging outcome, particularly considering the high median age and adverse risk profile of the study population.